PIPAC for Mesothelioma
Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is an experimental treatment that sprays chemotherapy into the abdomen. Doctors are studying it for peritoneal mesothelioma that cannot be removed with surgery. PIPAC may shrink tumors enough to allow surgery plus HIPEC, which may extend life expectancy.
Request a Free 2026 Mesothelioma Guide Free 2026 Mesothelioma Guide
What Is PIPAC Treatment?
PIPAC stands for pressurized intraperitoneal aerosol chemotherapy. It is an emerging form of mesothelioma treatment. PIPAC uses high pressure to push chemotherapy drugs into tumor tissue. Researchers are still studying whether this makes it work better than standard chemotherapy.
- PIPAC is an experimental treatment in the United States, mostly available through clinical trials at a small number of cancer centers.
- PIPAC sprays chemotherapy as a mist into the abdomen during minimally invasive surgery. It may shrink tumors that are too widespread to remove with surgery.
- In one study, more than half of patients who received PIPAC with standard chemotherapy were later able to have cytoreductive surgery with HIPEC.
- PIPAC delivers chemotherapy directly to the abdomen, so less of the drug reaches the rest of the body. This may mean fewer side effects.
Clinical trials are exploring PIPAC’s potential benefits for peritoneal mesothelioma patients. PIPAC treatment may help patients ineligible for cytoreductive surgery (CRS) become eligible. Early research also suggests it may help improve peritoneal mesothelioma symptoms.
PIPAC uses chemotherapy drugs to target tumor cells in the abdomen. The PIPAC procedure applies the drugs as a high-pressure aerosol. This is designed to help the drugs reach more tumor cells than standard chemotherapy methods.
Mesothelioma patients interested in PIPAC can discuss this procedure with their doctor. A mesothelioma doctor can help determine if a patient may be eligible for a PIPAC clinical trial.
PIPAC vs. HIPEC
PIPAC and hyperthermic intraperitoneal chemotherapy (HIPEC) are methods of administering chemotherapy to the abdominal cavity. Both methods treat peritoneal mesothelioma. HIPEC is a more common mesothelioma treatment than PIPAC. But PIPAC has qualities that may make it another useful treatment option. For example, it may help patients ineligible for CRS become eligible.
Both PIPAC and HIPEC administer chemotherapy drugs directly into the abdomen. PIPAC applies chemotherapy as a pressurized aerosol. HIPEC applies chemotherapy as a heated wash and is often combined with surgery. HIPEC plus surgery has proven effective in improving life expectancy for peritoneal mesothelioma patients.
Patients who undergo HIPEC procedures typically stay at the hospital for 10 – 12 days. Those who undergo PIPAC may be discharged on the same day as the procedure. Doctors will continue to monitor recovery after the patient is discharged.
Clinicians may use PIPAC as a step toward CRS plus HIPEC. For example, abdominal surgery may be too risky if a tumor is too large. PIPAC may help shrink tumors enough to make surgery plus HIPEC safer for patients.
PIPAC may also be an option for patients who are not yet healthy enough for surgery plus HIPEC. Surgery is taxing on the body and may require physical preparation in the weeks before the procedure. The surgery plus HIPEC procedure itself typically takes 6 – 12 hours, according to Mayo Clinic. PIPAC procedures usually last 1 – 2 hours and generally do not need special preparation.
How Does PIPAC Treat Mesothelioma?
PIPAC cancer treatment targets the abdomen, where peritoneal mesothelioma develops. This targeted application allows patients to receive a high concentration of chemotherapy. The pressure of the aerosolized drug can also enhance chemotherapy’s tumor cell-killing effect.
By turning the chemotherapy drug into a pressurized aerosol, PIPAC is designed to reach more cancer cells than other methods. When it comes to its mesothelioma cancer-targeting uses, PIPAC’s potential benefits include:
- Evenly applying chemotherapy: The pressurized aerosol helps spread chemotherapy more evenly through the abdomen than a liquid wash.
- Pushing chemotherapy farther into tumor tissue: Tumors may have natural resistance to the entry of fluids like regular chemotherapy. The pressure of the PIPAC application helps push chemotherapy into tumor tissue. This may help it penetrate deeper than traditional fluid chemotherapy solutions.
PIPAC Procedure
The PIPAC procedure consists of 4 steps: preparation, administration, port removal, and recovery. Patients undergoing PIPAC receive general anesthesia. This means the patient is asleep for the first 3 steps. The procedure usually lasts 1 – 2 hours.
PIPAC is a laparoscopic procedure. This means doctors perform it through 1 or 2 small punctures, also called access ports, in the patient’s abdomen.
The PIPAC procedure may follow these general steps:
- Preparation: Doctors first create the access port(s) for the procedure. They then use the port(s) to fill the abdominal cavity with carbon dioxide gas, which creates space to deliver the chemotherapy. They may also collect tumor biopsies and/or remove accumulated fluid. Finally, the doctors insert the device that applies pressurized chemotherapy into an access port.
- Administration: The pressurized, aerosolized chemotherapy is administered within the peritoneum for about 30 minutes. The excess chemotherapy gas is then flushed out through a waste management system.
- Port removal: Doctors remove all devices from a patient’s abdomen and close incisions.
- Recovery: Healthcare providers move the patient to a recovery room. The team monitors the patient until they are ready for discharge.
PIPAC treatment may involve different types of chemotherapy drugs. There is currently no standard drug or drug combination for PIPAC for mesothelioma. According to a 2026 review of 13 studies, most PIPAC studies in mesothelioma have used either cisplatin plus doxorubicin or oxaliplatin alone. Future clinical studies may explore different drugs or drug combinations for mesothelioma patients.
What to Expect After the PIPAC Procedure
After a PIPAC procedure, a patient may or may not have a hospital stay. Patients who do stay in the hospital may be there for 1 – 2 days.
A 2018 Danish study concluded that PIPAC can be performed in an outpatient setting. The study outlines the conditions for a patient being discharged on the day of surgery:
- Adequate pain relief
- Free mobility
- No anxiety or discomfort caused by leaving the hospital
- No urination problems
Patients may receive several rounds of PIPAC treatment every 6 – 8 weeks. There is currently no standard number of PIPAC treatment cycles for mesothelioma patients. In a 2022 study of 26 peritoneal mesothelioma patients, half received 3 or more PIPAC treatments. Some received as many as 15. The MESOTIP clinical trial planned 4 cycles of PIPAC, given every 6 weeks.
A patient’s care team decides how many PIPAC cycles are right for them. The team can also explain what to expect after treatment and help with recovery.
Benefits of PIPAC for Mesothelioma
Peritoneal mesothelioma patients may benefit from PIPAC. It is a newer procedure, but early PIPAC results point to several potential advantages. For example, some patients became eligible for surgery after PIPAC treatment. Surgery, especially if combined with HIPEC, may improve mesothelioma prognosis. In a 2009 international study of 405 peritoneal mesothelioma patients treated with surgery plus HIPEC, the median survival was 53 months. The 5-year survival rate was 47% in this same study.
PIPAC may also help improve mesothelioma symptoms. In a 2022 study of 26 peritoneal mesothelioma patients, PIPAC improved symptoms for 32% of patients. It also helped control fluid buildup, known as peritoneal effusion, in 46% of patients. Peritoneal effusion may cause various symptoms, such as abdominal pain.
Other benefits of PIPAC include:
- High concentration of chemotherapy: PIPAC increases the amount of chemotherapy in tumor tissue. This can help boost the cancer-fighting ability of chemotherapy drugs. PIPAC does this without causing a high blood concentration of the drug. This may lead to less organ damage than systemic chemotherapy.
- Gastrointestinal stability: Gastrointestinal symptoms usually do not get worse with PIPAC, although mild, short-term nausea or vomiting can happen. Gastrointestinal symptoms include nausea, vomiting, constipation, diarrhea, and loss of appetite.
- Low toxicity: PIPAC does not appear to cause serious liver or kidney damage. This suggests that it may be safe to administer multiple cycles of PIPAC. In a 2018 study of 43 patients who each had at least 3 PIPAC treatments, repeated PIPAC did not cause clinically relevant kidney damage.
Peritoneal mesothelioma patients interested in PIPAC should discuss the procedure with their doctor. Mesothelioma doctors can explain the potential benefits and side effects of PIPAC.
Questions About PIPAC Treatment for Mesothelioma? Ask experienced mesothelioma advocate Jennifer Lucarelli Ask a QuestionPIPAC Side Effects
Like other forms of mesothelioma cancer treatment, PIPAC may cause side effects. But it may cause fewer side effects than traditional, systemic chemotherapy. Some PIPAC patients have had the procedure more than once without major negative effects on their quality of life.
According to Mayo Clinic, most PIPAC side effects are mild and temporary. They may include:
- Abdominal pain or cramping
- Bloating
- Upset stomach or vomiting
Serious side effects are rare. They can include infection, injury to the bowel or other organs, and scar tissue that slows or blocks the intestines.
A 2026 review of 13 studies looked at the risks of PIPAC for peritoneal mesothelioma. About 8% of patients had a major complication. About 5% died soon after the procedure. Many patients in these studies had advanced cancer that had not responded to other treatments.
Common systemic chemotherapy side effects may be less likely with PIPAC. For instance, PIPAC patients do not typically report hair loss or worsening gastrointestinal symptoms.
Patients should talk to their care team about any side effects they experience. Their care team may be able to help manage treatment side effects.
PIPAC Clinical Trials
Research into PIPAC for mesothelioma and other cancers is ongoing. Results from clinical trials may help improve treatment for peritoneal mesothelioma. Patients who wish to join a PIPAC clinical trial can discuss eligibility with their doctor.
Early research suggests that PIPAC may be a useful part of a mesothelioma treatment plan. A 2022 French study looked at PIPAC in 26 peritoneal mesothelioma patients whose tumors could not be removed with surgery. Study patients received PIPAC in combination with systemic chemotherapy. Researchers concluded that PIPAC is a workable treatment to try to shrink tumors and help patients qualify for surgery.
After PIPAC, 14 of the 26 patients (54%) had cytoreductive surgery plus HIPEC. In all but one of these surgeries, doctors removed all visible tumor. Also, almost one-third of study participants reported improvement of symptoms.
Most of what we know about PIPAC for mesothelioma comes from small groups of patients who were carefully chosen for treatment. Those studies show PIPAC is possible for many patients and can shrink tumors in some. They cannot yet tell us whether it helps people live longer. That is the question a randomized trial is built to answer.
Francis Perry Wilson, MD
The MESOTIP trial is the first randomized trial of PIPAC for peritoneal mesothelioma. It tests PIPAC as a first-line treatment in two groups of patients. In early 2026, the trial was suspended after 3 patients in the PIPAC group developed febrile neutropenia, a fever with a dangerously low white blood cell count, according to ClinicalTrials.gov. Its estimated completion date is now June 2027.
- Control group: This group will receive cisplatin plus Alimta® (pemetrexed). This combination is a standard systemic chemotherapy treatment for mesothelioma patients.
- Experimental group: This group will receive standard systemic chemotherapy plus PIPAC with cisplatin and doxorubicin.
The results from this and other PIPAC clinical trials will provide valuable information for the mesothelioma community.
Who Is Eligible for PIPAC Treatment?
PIPAC is an emerging treatment for peritoneal mesothelioma. Patients may qualify for PIPAC clinical trials. Each clinical trial will have its own unique eligibility criteria.
In the United States, PIPAC is available at only a small number of specialized cancer centers, mostly through clinical trials, according to Mayo Clinic. The PIPAC device used in U.S. trials has not been approved by the U.S. Food and Drug Administration (FDA).
Early research suggests that PIPAC may be an option for patients ineligible for cytoreductive surgery (CRS). It is possible that PIPAC may help shrink tumors to the point where a patient becomes eligible for CRS. When combined with HIPEC, CRS can help improve some mesothelioma patients’ life expectancies.
Some patients may not be well enough to handle aggressive treatments. Mayo Clinic notes that PIPAC is less toxic than systemic chemotherapy and less invasive than open surgery. This may make it an option for patients in need of gentler forms of treatment.
Mesothelioma patients interested in PIPAC should talk to their doctors. A mesothelioma doctor can help patients determine eligibility to receive PIPAC treatment. They can also help patients explore other treatment options.
Common Questions About PIPAC for Mesothelioma
Is PIPAC a cure for mesothelioma?
Is PIPAC available in the United States?
How long do patients live after PIPAC?
Does insurance cover PIPAC?
Sources
Dr. Francis Perry Wilson is the Director of the Clinical and Translational Research Accelerator at the Yale University School of Medicine. He specializes in nephrology and clinical research.
Amy Zappone brings nearly two decades of experience in education and research-based communication. At Mesothelioma.com, she translates complex topics into understandable resources that help patients and families make informed decisions.